FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Healthcare & Life Sciences Enterprise Capital Monitor – USA – 08/2024”.
The Monitor is a month-to-month revealed overview of enterprise capital developments within the US Healthcare & Life Sciences sector.
As of the top of August 2024 we recognized the next present VC developments in the USA:
- Complete Healthcare & Life Sciences funding reached EUR 25,225m
- Biotech acquired 53% of the full funding quantity (EUR 13,281m) with oncology being the main indication (27%)
- In August Caresyntax secures the highest transaction quantity with EUR 285m, adopted by Halda Therapeutics with EUR 163m and IDRx with EUR 110m
- RA Capital Administration (United States) is probably the most energetic investor (by deal quantity), adopted by ARCH Enterprise Companions (United States) and F-Prime Capital (United States)
To entry the complete report, please click on right here.
By Mathias Klozenbücher und Johannes Hyperlink